Abstract
The minor-groove is an important receptor for enzymes and proteins involved in the processing and expression of genomic DNA. Small molecules capable of interfering with these processes by virtue of their ability to form adducts within the recognition sequences targeted by these enzymes/proteins have potential applications as cytotoxic and generegulating agents. Until recently, the targeting of the minor groove by platinum-based agents has been a widely unexplored opportunity. As part of this focused review on irreversible minor-groove modifying agents acting on adenine-N3, we summarize work performed in our laboratory and by our collaborators on a novel platinum-acridine conjugate, PTACRAMTU ([PtCl(en)(ACRAMTU)](NO3)2, en = ethane-1,2-diamine, ACRAMTU = 1-[2-(acridin-9-ylamino)ethyl]-1,3- dimethylthiourea, acridinium cation). The design of this agent as a non-cisplatin type pharmacophore has led to a groundbreaking discovery, the unprecedented intercalator-driven formation of platinum-adenine-N3 adducts in the minor groove of DNA. The minor-groove reactivity of PT-ACRAMTU represents a new paradigm in platinum-DNA interactions, which opens new avenues in the design of platinum-based therapeutics acting by a mechanism different from that of agents currently in clinical use.
Keywords: Platinum drugs, intercalators, minor-groove binders, cancer chemotherapy, adenine, transcription factor, acridine
Anti-Cancer Agents in Medicinal Chemistry
Title: Adenine-N3 in the DNA Minor Groove - An Emerging Target for Platinum Containing Anticancer Pharmacophores
Volume: 7 Issue: 1
Author(s): Rajsekhar Guddneppanavar and Ulrich Bierbach
Affiliation:
Keywords: Platinum drugs, intercalators, minor-groove binders, cancer chemotherapy, adenine, transcription factor, acridine
Abstract: The minor-groove is an important receptor for enzymes and proteins involved in the processing and expression of genomic DNA. Small molecules capable of interfering with these processes by virtue of their ability to form adducts within the recognition sequences targeted by these enzymes/proteins have potential applications as cytotoxic and generegulating agents. Until recently, the targeting of the minor groove by platinum-based agents has been a widely unexplored opportunity. As part of this focused review on irreversible minor-groove modifying agents acting on adenine-N3, we summarize work performed in our laboratory and by our collaborators on a novel platinum-acridine conjugate, PTACRAMTU ([PtCl(en)(ACRAMTU)](NO3)2, en = ethane-1,2-diamine, ACRAMTU = 1-[2-(acridin-9-ylamino)ethyl]-1,3- dimethylthiourea, acridinium cation). The design of this agent as a non-cisplatin type pharmacophore has led to a groundbreaking discovery, the unprecedented intercalator-driven formation of platinum-adenine-N3 adducts in the minor groove of DNA. The minor-groove reactivity of PT-ACRAMTU represents a new paradigm in platinum-DNA interactions, which opens new avenues in the design of platinum-based therapeutics acting by a mechanism different from that of agents currently in clinical use.
Export Options
About this article
Cite this article as:
Guddneppanavar Rajsekhar and Bierbach Ulrich, Adenine-N3 in the DNA Minor Groove - An Emerging Target for Platinum Containing Anticancer Pharmacophores, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/187152007779313991
DOI https://dx.doi.org/10.2174/187152007779313991 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 Vif: HIVs Weapon Against the Cellular Defense Factor APOBEC3G
Current HIV Research Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Mogroside V Inhibits Hyperglycemia-induced Lung Cancer Cells Metastasis through Reversing EMT and Damaging Cytoskeleton
Current Cancer Drug Targets Predicting Drug Efficacy Using Integrative Models for Chronic Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Current Cancer Drug Targets Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Reconsideration of Japanese Traditional Herbal Medicine: New Field of Research and Clinical Medicine
Mini-Reviews in Medicinal Chemistry Anti-Metastatic Effects of Lupeol via the Inhibition of MAPK/ERK Pathway in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL [Hot Topic: Modulation of the Immune System by Ionizing Irradiation and Chemotherapeutic Agents - Contribution of Immune Activation and Blocking of Immune Suppression to Cancer Therapy Success (Guest Editor: Udo S. Gaipl)]
Current Medicinal Chemistry Development and Validation of a Robust QSAR Model for Benzothiazole Hydrazone Derivatives as Bcl-XL Inhibitors
Letters in Drug Design & Discovery Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy Squalamine as an Example of a New Potent Antimicrobial Agents Class: A Critical Review
Current Medicinal Chemistry Isolation of a New Sesquiterpene Lactone From Vernonia Zeylanica (L) Less and its Anti-Proliferative Effects in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry